Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Open access

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8 + T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06063-y

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Individualized mRNA neoantigen vaccines are safe, feasible and immunogenic in patients with PDAC. a,b, Trial design (a) and consolidated standards of reporting trials diagram (b). c, Percentage of grade 3 AEs attributable to atezolizumab and autogene cevumeran (vaccine) in atezolizumab (n = 19) and vaccine (n = 16) safety-evaluable patients. Blue line indicates the study-defined safety threshold (25%). d, Achieved and benchmarked times to atezolizumab (left) and first vaccine dose (middle), and number of vaccine doses (right). Red line indicates the median, error bars are 95% confidence intervals and dotted lines the zone of clinical indifference. Asterisks indicate patients on study-specified treatment sequence. e–g, PBMCs collected after atezolizumab and before vaccine administration, 1–3 weeks after vaccine priming, and 5–6 weeks after mFOLFIRINOX were analysed for IFNγ+ T cells specific to all individual vaccine neoantigens by ex vivo IFNγ ELISpot in n = 16 patients in the biomarker-evaluable cohort. Patients were classified as responders if ELISpot detected IFNγ+ T cell induction against at least one vaccine neoantigen. e, Left, schematic and representative image of ex vivo IFNγ ELISpot. Middle, Number of vaccine neoantigens per patient that induced IFNγ+ T cells in PBMCs collected after vaccine priming. R0/R1 indicates the surgical margin status. For patient 25, 2 out of 5 ELISpot responses were detected against 2 neoantigen pools (pool 1 with 2 neoantigens, pool 2 with 5 neoantigens). Right, Proportion of vaccine responders and non-responders. f,g, Normalized ex vivo IFNγ ELISpot counts for vaccine neoantigens that induced a de novo response (n = 25 neoantigens in 8 patients): longitudinal (f, left); after priming (g). Spot counts of the non-stimulated controls were subtracted. Proportion of patients with monotope compared with polytope responses to all vaccine neoantigens (f, right). n indicates individual patients. Chemo, chemotherapy (mFOLFIRINOX). P values calculated using two-tailed unpaired t-test (d) or Wilcoxon matched-pairs signed-rank test (f). Source Data
Fig. 1 Individualized mRNA neoantigen vaccines are safe, feasible and immunogenic in patients with PDAC. a,b, Trial design (a) and consolidated standards of reporting trials diagram (b). c, Percentage of grade 3 AEs attributable to atezolizumab and autogene cevumeran (vaccine) in atezolizumab (n = 19) and vaccine (n = 16) safety-evaluable patients. Blue line indicates the study-defined safety threshold (25%). d, Achieved and benchmarked times to atezolizumab (left) and first vaccine dose (middle), and number of vaccine doses (right). Red line indicates the median, error bars are 95% confidence intervals and dotted lines the zone of clinical indifference. Asterisks indicate patients on study-specified treatment sequence. e–g, PBMCs collected after atezolizumab and before vaccine administration, 1–3 weeks after vaccine priming, and 5–6 weeks after mFOLFIRINOX were analysed for IFNγ+ T cells specific to all individual vaccine neoantigens by ex vivo IFNγ ELISpot in n = 16 patients in the biomarker-evaluable cohort. Patients were classified as responders if ELISpot detected IFNγ+ T cell induction against at least one vaccine neoantigen. e, Left, schematic and representative image of ex vivo IFNγ ELISpot. Middle, Number of vaccine neoantigens per patient that induced IFNγ+ T cells in PBMCs collected after vaccine priming. R0/R1 indicates the surgical margin status. For patient 25, 2 out of 5 ELISpot responses were detected against 2 neoantigen pools (pool 1 with 2 neoantigens, pool 2 with 5 neoantigens). Right, Proportion of vaccine responders and non-responders. f,g, Normalized ex vivo IFNγ ELISpot counts for vaccine neoantigens that induced a de novo response (n = 25 neoantigens in 8 patients): longitudinal (f, left); after priming (g). Spot counts of the non-stimulated controls were subtracted. Proportion of patients with monotope compared with polytope responses to all vaccine neoantigens (f, right). n indicates individual patients. Chemo, chemotherapy (mFOLFIRINOX). P values calculated using two-tailed unpaired t-test (d) or Wilcoxon matched-pairs signed-rank test (f). Source DataCC BY · PubMed Central
Fig. 2 mRNA vaccines expand polyclonal, polyfunctional effector CD8+ T cells. a, Vaccine-expanded T cell clones assessed using CloneTrack (top), vaccine-induced IFNγ by ELISpot (bottom) and their correlation (right). b,c, Vaccine-expanded clones identified by CloneTrack: longitudinal aggregate percentage (b), number of unique clones (c, left), before vaccine and peak expansion aggregate percentage (c, middle), and final per patient assessment times (bar graph) with aggregate percentage and clonal fraction at final assessment (c, right). For b, inverted triangles indicate collection times for single-cell sequencing in f and circles indicate vaccine booster. d, Immunodominant vaccine neoantigen-specific clonal overlap with vaccine-expanded clones and specificity to immunodominant vaccine-neoantigens by TCR cloning in patient 1. e, Left, Percentage of patients with immunodominant vaccine neoantigen-specific clones in vaccine-expanded clones. Right, Percentage of vaccine-expanded clones specific to immunodominant vaccine neoantigens. f, Single-cell phenotypes of vaccine-expanded CD8+ T cells. Dots indicate blood CD8+ T cells. Coloured dots (far left) indicate vaccine-expanded clones in a. g,h, Percentage of IFNγ+, TNF+ and CD107a+CD8+ (g,h) and CD4+ T cells (g) in PBMCs after vaccine priming with ex vivo immunodominant long (g) or minimal (h) neopeptide rechallenge. Representative flow plots from patient 1 (g, h). Pregated on CD3+CD56–CD8+ (g,h) or CD4+ (g) cells. i, Left, Aggregate percentage of vaccine-expanded clones with priming, chemotherapy and booster in peripheral blood. Right, Percentage of primed clones that re-expand with booster. n indicates individual clones or patients. In a and d, the green lines indicate individual clone trajectories; the black line, the geometric mean clonal trajectory (error bars are the geometric s.d.); the red line, the cumulative percentage of all expanded clones. In b,c, asterisks indicate altered treatment schedules. In b–d, rectangles indicate the treatment sequence. P values calculated using modified two-tailed Fisher’s exact test (a,d, left), two-sided Chi square test (a, right), two-tailed paired t-test (c), one-tailed binomial test with Bonferroni correction (d, middle) or two-tailed Wilcoxon matched-pairs signed-rank test (g–i). Source Data
Fig. 2 mRNA vaccines expand polyclonal, polyfunctional effector CD8+ T cells. a, Vaccine-expanded T cell clones assessed using CloneTrack (top), vaccine-induced IFNγ by ELISpot (bottom) and their correlation (right). b,c, Vaccine-expanded clones identified by CloneTrack: longitudinal aggregate percentage (b), number of unique clones (c, left), before vaccine and peak expansion aggregate percentage (c, middle), and final per patient assessment times (bar graph) with aggregate percentage and clonal fraction at final assessment (c, right). For b, inverted triangles indicate collection times for single-cell sequencing in f and circles indicate vaccine booster. d, Immunodominant vaccine neoantigen-specific clonal overlap with vaccine-expanded clones and specificity to immunodominant vaccine-neoantigens by TCR cloning in patient 1. e, Left, Percentage of patients with immunodominant vaccine neoantigen-specific clones in vaccine-expanded clones. Right, Percentage of vaccine-expanded clones specific to immunodominant vaccine neoantigens. f, Single-cell phenotypes of vaccine-expanded CD8+ T cells. Dots indicate blood CD8+ T cells. Coloured dots (far left) indicate vaccine-expanded clones in a. g,h, Percentage of IFNγ+, TNF+ and CD107a+CD8+ (g,h) and CD4+ T cells (g) in PBMCs after vaccine priming with ex vivo immunodominant long (g) or minimal (h) neopeptide rechallenge. Representative flow plots from patient 1 (g, h). Pregated on CD3+CD56–CD8+ (g,h) or CD4+ (g) cells. i, Left, Aggregate percentage of vaccine-expanded clones with priming, chemotherapy and booster in peripheral blood. Right, Percentage of primed clones that re-expand with booster. n indicates individual clones or patients. In a and d, the green lines indicate individual clone trajectories; the black line, the geometric mean clonal trajectory (error bars are the geometric s.d.); the red line, the cumulative percentage of all expanded clones. In b,c, asterisks indicate altered treatment schedules. In b–d, rectangles indicate the treatment sequence. P values calculated using modified two-tailed Fisher’s exact test (a,d, left), two-sided Chi square test (a, right), two-tailed paired t-test (c), one-tailed binomial test with Bonferroni correction (d, middle) or two-tailed Wilcoxon matched-pairs signed-rank test (g–i). Source DataCC BY · PubMed Central
Fig. 3 mRNA vaccine response correlates with delayed PDAC recurrence. a, OS and RFS in n = 19 patients in the safety-evaluable cohort. b, RFS from surgery and from landmark time (date of the last vaccine priming dose) stratified by vaccine response in patients in the biomarker-evaluable cohort. n indicates individual patients. HR indicates hazard ratio with 95% CI. P values calculated using two-tailed log-rank test.
Fig. 3 mRNA vaccine response correlates with delayed PDAC recurrence. a, OS and RFS in n = 19 patients in the safety-evaluable cohort. b, RFS from surgery and from landmark time (date of the last vaccine priming dose) stratified by vaccine response in patients in the biomarker-evaluable cohort. n indicates individual patients. HR indicates hazard ratio with 95% CI. P values calculated using two-tailed log-rank test.CC BY · PubMed Central
Fig. 4 Vaccine-expanded T cells can infiltrate a micrometastasis. Clinical and immunological snapshot of a disappearing intrahepatic lymphoid aggregate after vaccination in a patient who responded to the vaccine. a, Serial percentage of vaccine-expanded T cells in blood analysed using CloneTrack and serum CA19-9 (left), and abdominal MRI (right) before and after vaccination. b, Haematoxylin and eosin staining (left), multiplexed immunofluorescence (middle) and percentage of vaccine-expanded T cells measured using CloneTrack (right, grey bar) in a new liver lesion that developed after vaccination detected by MRI as in a. All 15 vaccine-expanded T cell clones (a, red line) were present in liver lesion (right, grey bar). c, Percentage of mutant TP53R175H reads by digital droplet PCR in the liver lesion. The bar indicates the median, the error bars are the s.e.m. d, Uniform manifold approximation and projection (UMAP) plots of single-cell phenotypes of all blood T cells (left) and vaccine-expanded clones (middle), with effector markers (right). n indicates the number of T cells detected in liver lesion (b) or technical replicates (c). Data represent analyses of a single patient. Source Data
Fig. 4 Vaccine-expanded T cells can infiltrate a micrometastasis. Clinical and immunological snapshot of a disappearing intrahepatic lymphoid aggregate after vaccination in a patient who responded to the vaccine. a, Serial percentage of vaccine-expanded T cells in blood analysed using CloneTrack and serum CA19-9 (left), and abdominal MRI (right) before and after vaccination. b, Haematoxylin and eosin staining (left), multiplexed immunofluorescence (middle) and percentage of vaccine-expanded T cells measured using CloneTrack (right, grey bar) in a new liver lesion that developed after vaccination detected by MRI as in a. All 15 vaccine-expanded T cell clones (a, red line) were present in liver lesion (right, grey bar). c, Percentage of mutant TP53R175H reads by digital droplet PCR in the liver lesion. The bar indicates the median, the error bars are the s.e.m. d, Uniform manifold approximation and projection (UMAP) plots of single-cell phenotypes of all blood T cells (left) and vaccine-expanded clones (middle), with effector markers (right). n indicates the number of T cells detected in liver lesion (b) or technical replicates (c). Data represent analyses of a single patient. Source DataCC BY · PubMed Central
Extended Data Fig. 1 Patient demographics, clinical characteristics, and toxicity. (A, B) Demographics and clinical characteristics of all evaluable patients (n = 19) (A) and biomarker-evaluable patients (n = 16) stratified by autogene cevumeran responders and non-responders (B). (C) Frequency of grade 1 and 2 adverse events attributable to atezolizumab (left) and vaccine (right) in evaluable patients who received each drug. n = individual patients. Data are n (%) unless noted. P values by two-tailed Mann-Whitney test for numerical variables and Fisher’s exact test for categorical variables. Source Data
Extended Data Fig. 1 Patient demographics, clinical characteristics, and toxicity. (A, B) Demographics and clinical characteristics of all evaluable patients (n = 19) (A) and biomarker-evaluable patients (n = 16) stratified by autogene cevumeran responders and non-responders (B). (C) Frequency of grade 1 and 2 adverse events attributable to atezolizumab (left) and vaccine (right) in evaluable patients who received each drug. n = individual patients. Data are n (%) unless noted. P values by two-tailed Mann-Whitney test for numerical variables and Fisher’s exact test for categorical variables. Source DataCC BY · PubMed Central
Extended Data Fig. 2 Immunogenic autogene cevumeran neoantigens. (A) Frequency of immunogenic autogene cevumeran (vaccine) neoantigens in all patients (left) and in vaccine responders (right). (B) Number of immunogenic vaccine neoantigens per patient. (C) Number of non-synonymous mutations (left) and vaccine neoantigens (right) in vaccine responders and non-responders. (D) Vaccine-expanded T cell clones by CloneTrack in non-responders. n = neoantigens or patients as noted. P values by two-tailed Mann-Whitney test (C) and modified two-tailed Fisher’s exact test (D). Source Data
Extended Data Fig. 2 Immunogenic autogene cevumeran neoantigens. (A) Frequency of immunogenic autogene cevumeran (vaccine) neoantigens in all patients (left) and in vaccine responders (right). (B) Number of immunogenic vaccine neoantigens per patient. (C) Number of non-synonymous mutations (left) and vaccine neoantigens (right) in vaccine responders and non-responders. (D) Vaccine-expanded T cell clones by CloneTrack in non-responders. n = neoantigens or patients as noted. P values by two-tailed Mann-Whitney test (C) and modified two-tailed Fisher’s exact test (D). Source DataCC BY · PubMed Central
Extended Data Fig. 3 Autogene cevumeran–expanded T cell clones do not overlap with atezolizumab-expanded T cell clones. (A) Cumulative percentage of atezolizumab-expanded T cells by CloneTrack in autogene cevumeran (vaccine) responders and non-responders. * = altered treatment schedules for patients 3, 4, 14 and 18. (B) Atezolizumab-expanded T cell clones by CloneTrack in vaccine responders and non-responders. Red box = atezolizumab responder. Blue line = trajectory of an individual atezolizumab-expanded clone. Black line = geometric mean trajectory of all atezolizumab-expanded clones; error bars = geometric standard deviation. Red line = cumulative percentage of all atezolizumab-expanded clones. Black rectangle/triangle = time of surgery; blue rectangle/triangle = time of atezolizumab; green rectangle/triangle = times of autogene cevumeran (vaccine); yellow bars = mFOLFIRINOX cycles. (C) Venn diagrams show overlap of vaccine-expanded clones (as identified in Fig. 2a) with atezolizumab-expanded clones in vaccine responders and non-responders. n = number of clones or individual patients as noted. P values by modified two-tailed Fisher’s exact test (B). Source Data
Extended Data Fig. 3 Autogene cevumeran–expanded T cell clones do not overlap with atezolizumab-expanded T cell clones. (A) Cumulative percentage of atezolizumab-expanded T cells by CloneTrack in autogene cevumeran (vaccine) responders and non-responders. * = altered treatment schedules for patients 3, 4, 14 and 18. (B) Atezolizumab-expanded T cell clones by CloneTrack in vaccine responders and non-responders. Red box = atezolizumab responder. Blue line = trajectory of an individual atezolizumab-expanded clone. Black line = geometric mean trajectory of all atezolizumab-expanded clones; error bars = geometric standard deviation. Red line = cumulative percentage of all atezolizumab-expanded clones. Black rectangle/triangle = time of surgery; blue rectangle/triangle = time of atezolizumab; green rectangle/triangle = times of autogene cevumeran (vaccine); yellow bars = mFOLFIRINOX cycles. (C) Venn diagrams show overlap of vaccine-expanded clones (as identified in Fig. 2a) with atezolizumab-expanded clones in vaccine responders and non-responders. n = number of clones or individual patients as noted. P values by modified two-tailed Fisher’s exact test (B). Source DataCC BY · PubMed Central
Extended Data Fig. 4 Autogene cevumeran–expanded T cell clones contain immunodominant neoantigen-specific T cells. (A, B) Autogene cevumeran (vaccine) induced IFNγ production by ex vivo IFNγ ELISpot (assay schematic, Fig. 1e) and clonal expansion by CloneTrack (assay schematic, B, top). Briefly, for ELISpot, we analyzed each patient’s PBMCs for specific T cells against all individual vaccine neoantigens post-atezolizumab/pre-vaccine, 1-3 weeks post-vaccine priming doses, and 5-6 weeks post-mFOLFIRINOX. Each patient’s PBMCs were stimulated overnight with separate pools of overlapping peptides (15 amino acids long), each pool representing one of up to 20 neoantigens in vaccines, or with anti-CD3 antibody as a positive control, followed by measurement of IFNγ production by ELISpot. PBMCs incubated with media alone were used as a negative control. To track T cell clones, we identified vaccine-expanded T cell clones with CloneTrack. To identify if expanded clones contained immunodominant neoantigen-specific clones, in 4 of 8 responders, we stimulated vaccine-expanded PBMCs collected 1-3 weeks post-vaccine priming doses in vitro with computationally predicted minimal neopeptide pools (8-14 amino acids long) from 6 neoantigens that generated the highest per-patient magnitude response by ex vivo IFNγ ELISpot. We then purified CD8+ T cells that either expressed or did not express the degranulation marker CD107a, identified clones with greater proportion of CD107a+ versus CD107a- cells as in vitro neoepitope-activated clones, and examined overlap of in vitro neoepitope-activated to in vivo vaccine-expanded clones (Venn diagrams). For select patients, we further validated neoepitope-specificity by TCR cloning. (A) Flow cytometry gating strategies. (B) Ex vivo IFNγ ELISpot and T cell clonal expansion by CloneTrack in n = 3 of 4 patients tested (fourth patient in Fig. 2d). (B, left) Normalized ex vivo IFNγ ELISpot spot count per 1 x 106 PBMCs for each immunogenic neoantigen in patients 10, 11 and 5. In patient 5, one neoantigen induced a high magnitude T cell response, while patients 10 and 11 had polytopic high magnitude responses against 8 and 3 vaccine neoantigens respectively. Black lines = individual neoantigens; coloured lines = neoantigen pools. (B, middle): T cell clonal expansion in patients 10, 11 and 5 by CloneTrack. Green line = trajectory of an individual expanded clone. Black line = geometric mean trajectory of all expanded clones; error bars = geometric standard deviation. Red line = cumulative percentage of all expanded clones. Black triangle = time of surgery; blue triangle = time of atezolizumab; green triangles = times of autogene cevumeran (vaccine); yellow bars = mFOLFIRINOX cycles. Dotted black line = detection threshold. (B, right): In vitro neoantigen-specific activation. Flow cytometry = CD107a expression on CD8+ T cells stimulated with neopeptides or control (DMSO). Dot plots = number of CD107a+ versus CD107a- cells per T cell clone. Each circle = individual T cell clone. Green/blue squares = clones also detected by CloneTrack. Diagonal: CD107a+ clone frequency = CD107a- clone frequency. Venn diagram = vaccine-expanded and in vitro neoantigen-specific clonal overlap. For patient 11, immunodominant neoantigen-specific clones resided in a lower magnitude vaccine-expanded clonal pool. (B, right, bottom) TCR cloning, patient 10: 4-1BB expression on putative neoantigen-specific TCR-transduced CD8+ T cells cultured with HLA-matched, neopeptide-pulsed antigen presenting cells (HLA-transduced K562 cells). n = number of clones. P values by modified two-tailed Fisher’s exact test (B, middle), and by one-tailed binomial test with Bonferroni correction (B, right). Source Data
Extended Data Fig. 4 Autogene cevumeran–expanded T cell clones contain immunodominant neoantigen-specific T cells. (A, B) Autogene cevumeran (vaccine) induced IFNγ production by ex vivo IFNγ ELISpot (assay schematic, Fig. 1e) and clonal expansion by CloneTrack (assay schematic, B, top). Briefly, for ELISpot, we analyzed each patient’s PBMCs for specific T cells against all individual vaccine neoantigens post-atezolizumab/pre-vaccine, 1-3 weeks post-vaccine priming doses, and 5-6 weeks post-mFOLFIRINOX. Each patient’s PBMCs were stimulated overnight with separate pools of overlapping peptides (15 amino acids long), each pool representing one of up to 20 neoantigens in vaccines, or with anti-CD3 antibody as a positive control, followed by measurement of IFNγ production by ELISpot. PBMCs incubated with media alone were used as a negative control. To track T cell clones, we identified vaccine-expanded T cell clones with CloneTrack. To identify if expanded clones contained immunodominant neoantigen-specific clones, in 4 of 8 responders, we stimulated vaccine-expanded PBMCs collected 1-3 weeks post-vaccine priming doses in vitro with computationally predicted minimal neopeptide pools (8-14 amino acids long) from 6 neoantigens that generated the highest per-patient magnitude response by ex vivo IFNγ ELISpot. We then purified CD8+ T cells that either expressed or did not express the degranulation marker CD107a, identified clones with greater proportion of CD107a+ versus CD107a- cells as in vitro neoepitope-activated clones, and examined overlap of in vitro neoepitope-activated to in vivo vaccine-expanded clones (Venn diagrams). For select patients, we further validated neoepitope-specificity by TCR cloning. (A) Flow cytometry gating strategies. (B) Ex vivo IFNγ ELISpot and T cell clonal expansion by CloneTrack in n = 3 of 4 patients tested (fourth patient in Fig. 2d). (B, left) Normalized ex vivo IFNγ ELISpot spot count per 1 x 106 PBMCs for each immunogenic neoantigen in patients 10, 11 and 5. In patient 5, one neoantigen induced a high magnitude T cell response, while patients 10 and 11 had polytopic high magnitude responses against 8 and 3 vaccine neoantigens respectively. Black lines = individual neoantigens; coloured lines = neoantigen pools. (B, middle): T cell clonal expansion in patients 10, 11 and 5 by CloneTrack. Green line = trajectory of an individual expanded clone. Black line = geometric mean trajectory of all expanded clones; error bars = geometric standard deviation. Red line = cumulative percentage of all expanded clones. Black triangle = time of surgery; blue triangle = time of atezolizumab; green triangles = times of autogene cevumeran (vaccine); yellow bars = mFOLFIRINOX cycles. Dotted black line = detection threshold. (B, right): In vitro neoantigen-specific activation. Flow cytometry = CD107a expression on CD8+ T cells stimulated with neopeptides or control (DMSO). Dot plots = number of CD107a+ versus CD107a- cells per T cell clone. Each circle = individual T cell clone. Green/blue squares = clones also detected by CloneTrack. Diagonal: CD107a+ clone frequency = CD107a- clone frequency. Venn diagram = vaccine-expanded and in vitro neoantigen-specific clonal overlap. For patient 11, immunodominant neoantigen-specific clones resided in a lower magnitude vaccine-expanded clonal pool. (B, right, bottom) TCR cloning, patient 10: 4-1BB expression on putative neoantigen-specific TCR-transduced CD8+ T cells cultured with HLA-matched, neopeptide-pulsed antigen presenting cells (HLA-transduced K562 cells). n = number of clones. P values by modified two-tailed Fisher’s exact test (B, middle), and by one-tailed binomial test with Bonferroni correction (B, right). Source DataCC BY · PubMed Central
Extended Data Fig. 5 Autogene cevumeran activates neoantigen-specific polyfunctional effector CD8+ T cells. (A) Uniform manifold approximation and projection (UMAP) plots of single peripheral blood T cells by single-cell RNA/TCR sequencing in n = 4 patients (patients 1, 10, 11 and 29) stratified by lineage (CD8 vs. CD4, left), patient (middle), and vaccine-expanded clones (right; expanded clones identified in Fig. 2a). T cells purified post-vaccine priming doses at time points indicated in Fig. 2b (inverted triangles). (B, C) UMAP plots of single peripheral blood CD8+ T cells in patients 1, 10, 11 and 29 stratified by CD8+ T cell naïve (SELL, CCR7, IL7R, BCL2, PECAM1, TCF7, BACH2, LEF1), dysfunctional (TIGIT, TOX, LAG3, ENTPD1, CXCL13, HAVCR2, GZMB), memory (EOMES, GZMK, CXCR3, TCF1, ID3, STAT4, CCR7, SELL) and effector (PRF1, GZMB, GNLY, IFNγ, EOMES, ZEB2, E2F7, TBX21, PDCD1, CXCR3, FAS) transcriptional phenotypes (B) and select individual phenotype defining markers (C). (D) Cytokine (IFNγ, TNFα) production in CD8+ and CD4+ T cells after post-vaccine bulk PBMC ex vivo rechallenge with pools of overlapping long neopeptides. (E) Cytokine (IFNγ, TNFα) production and degranulation (CD107a) by CD8+ T cells after bulk PBMC ex vivo rechallenge with predicted minimal neopeptides. Flow cytometry gating strategies as in Extended Data Fig. 4a. (F) Peripheral blood CD8+ T cell proliferation (Ki67) and activation (PD-1, LAG-3, TIM-3, HLA-DR) pre- and serially post-atezolizumab, vaccine and mFOLFIRINOX by flow cytometry in n = 7 of 8 responders and n = 7 of 8 non-responders with available data. n = number of patients. Source Data
Extended Data Fig. 5 Autogene cevumeran activates neoantigen-specific polyfunctional effector CD8+ T cells. (A) Uniform manifold approximation and projection (UMAP) plots of single peripheral blood T cells by single-cell RNA/TCR sequencing in n = 4 patients (patients 1, 10, 11 and 29) stratified by lineage (CD8 vs. CD4, left), patient (middle), and vaccine-expanded clones (right; expanded clones identified in Fig. 2a). T cells purified post-vaccine priming doses at time points indicated in Fig. 2b (inverted triangles). (B, C) UMAP plots of single peripheral blood CD8+ T cells in patients 1, 10, 11 and 29 stratified by CD8+ T cell naïve (SELL, CCR7, IL7R, BCL2, PECAM1, TCF7, BACH2, LEF1), dysfunctional (TIGIT, TOX, LAG3, ENTPD1, CXCL13, HAVCR2, GZMB), memory (EOMES, GZMK, CXCR3, TCF1, ID3, STAT4, CCR7, SELL) and effector (PRF1, GZMB, GNLY, IFNγ, EOMES, ZEB2, E2F7, TBX21, PDCD1, CXCR3, FAS) transcriptional phenotypes (B) and select individual phenotype defining markers (C). (D) Cytokine (IFNγ, TNFα) production in CD8+ and CD4+ T cells after post-vaccine bulk PBMC ex vivo rechallenge with pools of overlapping long neopeptides. (E) Cytokine (IFNγ, TNFα) production and degranulation (CD107a) by CD8+ T cells after bulk PBMC ex vivo rechallenge with predicted minimal neopeptides. Flow cytometry gating strategies as in Extended Data Fig. 4a. (F) Peripheral blood CD8+ T cell proliferation (Ki67) and activation (PD-1, LAG-3, TIM-3, HLA-DR) pre- and serially post-atezolizumab, vaccine and mFOLFIRINOX by flow cytometry in n = 7 of 8 responders and n = 7 of 8 non-responders with available data. n = number of patients. Source DataCC BY · PubMed Central
Extended Data Fig. 6 Post-mFOLFIRINOX autogene cevumeran booster re-expands primed T cell clones. (A) CloneTrack-identified autogene cevumeran (vaccine) expanded T cell clones with vaccine priming, mFOLFIRINOX chemotherapy (chemo) and vaccine booster. Data shown for patients that had detectable vaccine-expanded clones and received the vaccine booster. (B) Percentage of vaccine-expanded T cell clones that are detectable and re-expand with vaccine booster in responders. n = number of patients or clones. Source Data
Extended Data Fig. 6 Post-mFOLFIRINOX autogene cevumeran booster re-expands primed T cell clones. (A) CloneTrack-identified autogene cevumeran (vaccine) expanded T cell clones with vaccine priming, mFOLFIRINOX chemotherapy (chemo) and vaccine booster. Data shown for patients that had detectable vaccine-expanded clones and received the vaccine booster. (B) Percentage of vaccine-expanded T cell clones that are detectable and re-expand with vaccine booster in responders. n = number of patients or clones. Source DataCC BY · PubMed Central
Extended Data Fig. 7 Autogene cevumeran responders evidence lower post-vaccination serum CA19-9, equivalent chemotherapy doses and comparable intratumoural T cells. (A, B) Fraction of biomarker-evaluable patients with detectable CA19-9 (A) or circulating tumour DNA (ctDNA) (B) in the peripheral blood at diagnosis. Longitudinal serum CA19-9 levels in autogene cevumeran (vaccine) responders and non-responders (A, bottom). Circle = mean, error bars = standard error of the mean (C) Recurrence-free survival (RFS) stratified by atezolizumab response (left) and median primary tumour size (right). (D) Number of cycles of mFOLFIRINOX (chemotherapy) in vaccine responders and non-responders. (E) Intratumoural T cell infiltration in autogene cevumeran responders and non-responders. n = individual patients. P values by two-tailed Mann Whitney test (A), and log-rank test (C). Source Data
Extended Data Fig. 7 Autogene cevumeran responders evidence lower post-vaccination serum CA19-9, equivalent chemotherapy doses and comparable intratumoural T cells. (A, B) Fraction of biomarker-evaluable patients with detectable CA19-9 (A) or circulating tumour DNA (ctDNA) (B) in the peripheral blood at diagnosis. Longitudinal serum CA19-9 levels in autogene cevumeran (vaccine) responders and non-responders (A, bottom). Circle = mean, error bars = standard error of the mean (C) Recurrence-free survival (RFS) stratified by atezolizumab response (left) and median primary tumour size (right). (D) Number of cycles of mFOLFIRINOX (chemotherapy) in vaccine responders and non-responders. (E) Intratumoural T cell infiltration in autogene cevumeran responders and non-responders. n = individual patients. P values by two-tailed Mann Whitney test (A), and log-rank test (C). Source DataCC BY · PubMed Central
Extended Data Fig. 8 Autogene cevumeran responders and non-responders have equivalent humoral and cellular responses to an unrelated mRNA vaccine. (Top left) Anti-SARS-CoV-2 spike IgG in sera of vaccine responders and non-responders before (pre), after priming (post-prime) and after booster (post-boost early and late) doses of COVID-19 mRNA vaccine (Pfizer-BioNTech BNT162b2 or Moderna Spikevax). (Top right) Serial PBMCs pre- and post-COVID-19 mRNA vaccination were stimulated with SARS CoV-2 peptide pools. SARS CoV-2-specific IFNγ and/or TNFα production by all T cells was measured by flow cytometry. Composite data (top right) with representative gating (bottom) are shown. Flow cytometry pre-gated on CD3+ CD56− cells. Circle = mean, error bars = standard error of the mean; n = individual patients; data shown for all patients with available samples. P values by two-tailed Wilcoxon matched-pairs signed rank test. Source Data
Extended Data Fig. 8 Autogene cevumeran responders and non-responders have equivalent humoral and cellular responses to an unrelated mRNA vaccine. (Top left) Anti-SARS-CoV-2 spike IgG in sera of vaccine responders and non-responders before (pre), after priming (post-prime) and after booster (post-boost early and late) doses of COVID-19 mRNA vaccine (Pfizer-BioNTech BNT162b2 or Moderna Spikevax). (Top right) Serial PBMCs pre- and post-COVID-19 mRNA vaccination were stimulated with SARS CoV-2 peptide pools. SARS CoV-2-specific IFNγ and/or TNFα production by all T cells was measured by flow cytometry. Composite data (top right) with representative gating (bottom) are shown. Flow cytometry pre-gated on CD3+ CD56− cells. Circle = mean, error bars = standard error of the mean; n = individual patients; data shown for all patients with available samples. P values by two-tailed Wilcoxon matched-pairs signed rank test. Source DataCC BY · PubMed Central
Extended Data Fig. 9 Autogene cevumeran responders and non-responders have equivalent frequencies of circulating immune cells. (A-C) Longitudinal frequencies of regulatory T cells (A), innate (B) and adaptive (C) immune cells in the peripheral blood of autogene cevumeran responders and non-responders during vaccination. Analyses in n = 13 patients with identical study-specified treatment schedules and thus eligible for direct comparison. Circle = mean, error bars = standard error of the mean; n = individual patients. P values by two-tailed Mann Whitney test. Source Data
Extended Data Fig. 9 Autogene cevumeran responders and non-responders have equivalent frequencies of circulating immune cells. (A-C) Longitudinal frequencies of regulatory T cells (A), innate (B) and adaptive (C) immune cells in the peripheral blood of autogene cevumeran responders and non-responders during vaccination. Analyses in n = 13 patients with identical study-specified treatment schedules and thus eligible for direct comparison. Circle = mean, error bars = standard error of the mean; n = individual patients. P values by two-tailed Mann Whitney test. Source DataCC BY · PubMed Central
Extended Data Fig. 10 Tumour clonality and neoantigen quality in biomarker-evaluable patients, and mutated TP53 in a disappearing liver lesion. (A) Shannon entropy (S) of tumour clones in autogene cevumeran (vaccine) responders and non-responders. (B) Receiver operating curve indicating the ability of neoantigen quality as a continuous variable to classify vaccine neoantigens as an inducer or non-inducer of an IFNγ ELISpot response. Dotted line = all neoantigens included in individualized mRNA vaccines. (C) Digital droplet PCR showing number of wild-type (WT) TP53, or R175H mutated TP53 droplets in liver lesion from patient 29 (Fig. 4), with positive and negative (gDNA) controls. n = individual patients (A) or neoantigens (B). P values by two-tailed Mann-Whitney test. Source Data
Extended Data Fig. 10 Tumour clonality and neoantigen quality in biomarker-evaluable patients, and mutated TP53 in a disappearing liver lesion. (A) Shannon entropy (S) of tumour clones in autogene cevumeran (vaccine) responders and non-responders. (B) Receiver operating curve indicating the ability of neoantigen quality as a continuous variable to classify vaccine neoantigens as an inducer or non-inducer of an IFNγ ELISpot response. Dotted line = all neoantigens included in individualized mRNA vaccines. (C) Digital droplet PCR showing number of wild-type (WT) TP53, or R175H mutated TP53 droplets in liver lesion from patient 29 (Fig. 4), with positive and negative (gDNA) controls. n = individual patients (A) or neoantigens (B). P values by two-tailed Mann-Whitney test. Source DataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 1,432

Metadata

Authors
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., Müller, F., Rhee, I., Yadav, M., Dobrin, A., Sadelain, M., Łuksza, M., Cohen, N., Tang, L., Basturk, O., Gönen, M., Katz, S., Do, R. K., Epstein, A. S., Momtaz, P., Park, W., Sugarman, R., Varghese, A. M., Won, E., Desai, A., Wei, A. C., D’Angelica, M. I., Kingham, T. P., Mellman, I., Merghoub, T., Wolchok, J. D., Sahin, U., Türeci, Ö., Greenbaum, B. D., Jarnagin, W. R., Drebin, J., O’Reilly, E. M., & Balachandran, V. P.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • BioNTech (Germany) (DE)
  • Genentech (US)
  • Tisch Cancer Institute (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Weill Cornell Medicine (US)
Corresponding author
  • Greenbaum, Benjamin D.
  • Balachandran, Vinod P.
Venue
Nature
Published
2023-05-10
Volume
618
Issue
7963
Pages
144-150
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4376133743
Cited by
1,432
References
63
Citations by year
2026: 426 · 2025: 488 · 2024: 381 · 2023: 136
FWCI
156.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Damon Runyon Cancer Research Foundation
  • Lustgarten Foundation
  • Pershing Square Sohn Cancer Research Alliance
  • Cycle for Survival
  • National Institutes of Health (CA08748, CCSG, P30 CA08748)
  • Genentech
  • Stand Up To Cancer
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology
  • National Cancer Institute (U01CA224175, P30-CA-08748, CA08748, CA224175, P30CA008748, CCSG P30 CA08748)
  • Moonshot Research and Development Program
  • Cancer Moonshot
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
pancreatic ductal adenocarcinoma, personalized neoantigen vaccine, mRNA vaccines, atezolizumab, modified FOLFIRINOX, neoantigen-specific T cells, CD8+ T cells, recurrence-free survival, adjuvant immunotherapy, immune fitness, COVID-19 mRNA vaccine
MeSH terms
mRNA Vaccines, Adjuvants, Immunologic, Antigens, Neoplasm, Humans, Immunotherapy, Lymphocyte Activation, Pancreatic Neoplasms, T-Lymphocytes, CD8-Positive T-Lymphocytes, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41586-023-06063-y
The paper
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., . . . Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. https://doi.org/10.1038/s41586-023-06063-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.